Recurrence of local tumour bed in patients who underwent partial nephrectomy correlates with several preoperative factors, such as gender, multiple tumours and a solitary kidney, in addition to intra- and postoperative factors including a positive surgical margin, and higher pathological stage and nephrometry score, according to a recent study.
Chinese patients with metastatic castration-resistant prostate cancer (mCRPC) have higher response rates, longer survival and a lower risk of fatigue when enzalutamide is used in earlier rather than later lines of treatment, a study by the Hong Kong Society of Uro-Oncology has shown.
Adding docetaxel to androgen deprivation therapy (ADT) can prevent prostate-specific antigen (PSA) progression and delay the development of castration resistance in Chinese patients with metastatic hormone-naïve prostate cancer, a study by the Chinese University of Hong Kong (CUHK) has shown.
Findings of recently completed trials have shown that atezolizumab and pembrolizumab could be possible first-line therapy options for cisplatin-ineligible patients with advanced and metastatic urothelial carcinoma, according to a presentation at the Hong Kong Society of Uro-Oncology Annual Scientific Meeting 2018.
Researchers have developed a new polygenic hazard score, which has been validated by an independent dataset, for assessing personalized genetic risk that can predict age at onset of aggressive prostate cancer, reports a study.
The minimally invasive convective radiofrequency (RF) thermal therapy appears to provide early and durable relief of lower urinary tract symptoms in patients with benign prostatic hyperplasia (BPH), according to a team of US-based researchers. In addition, the procedure allows preservation of sexual function and can be performed on the median lobe and hyperplastic central zone tissue.
Long-term treatment with testosterone undecanoate (TU) in hypogonadal men with type 2 diabetes (T2D) resulted in substantial and sustained weight loss compared with untreated individuals, according to registry studies presented at the IDF 2017.
In support of the Blue Cap Movement, GlaxoSmithKline (GSK) Pharmaceutical Sdn Bhd embarks on a partnership with the Malaysian Urological Association (MUA) and Malaysian Medical Association (MMA) to further promote awareness and education on benign prostatic hyperplasia (BPH).
In Asian patients with localized prostate cancer, high dose rate (HDR) brachytherapy following an external beam radiotherapy (EBRT) achieves effective disease control while minimizing toxicity, a recent Singapore study has shown.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.